News Changing Faces: biopharma hires from November 2022 The month of November saw a number of notable hires and personnel moves in biotech and
News Atriva takes MEK inhibitor into phase 2 for COVID-19 Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
